StockNews.com began coverage on shares of Veradigm (NASDAQ:MDRX - Free Report) in a research report released on Tuesday. The brokerage issued a hold rating on the software maker's stock.
Separately, Stephens lifted their target price on shares of Veradigm from $7.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Friday, January 31st.
View Our Latest Analysis on Veradigm
Veradigm Stock Up 4.9 %
Veradigm stock traded up $0.20 during trading hours on Tuesday, hitting $4.25. The stock had a trading volume of 278,785 shares, compared to its average volume of 487,759. Veradigm has a 1-year low of $4.00 and a 1-year high of $11.80. The stock's fifty day moving average is $5.67 and its two-hundred day moving average is $8.35.
Veradigm Company Profile
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
See Also
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
